Business News • PR NewsWire • ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival

ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival

ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival

While the disease has progressed in all patients receiving standard of care, it did not progress in 40% of the patients receiving standard chemotherapy together with the experimental drug, Elenagen — and for half of the patients in the group, Elenagen has increased the time to disease...

View More : https://www.prnewswire.com:443/news-releases/esmo-2022-interim-results-for-treatment-of-platinum-resistant-ovarian-cance...

Releted News by prnewswire

USD 2.36 Bn growth expected in Nut Meals Market -- Driven by increasing demand from millennials

Global Times: China's economy set to get a major boost from 20th Party Congress, to anchor global economy in long run

Global Retail Pos Terminals Market to value USD 60 Bn by 2030, Predicts Global Market Insights Inc.

How Global Private 5G Networks Lead Enterprises to a New Level

Electrolux: Cost reduction program and management changes